As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.
30 Analysts have issued a Tandem Diabetes Care, Inc. forecast:
30 Analysts have issued a Tandem Diabetes Care, Inc. forecast:
Jun '25 |
+/-
%
|
||
Revenue | 1,002 1,002 |
26%
26%
|
|
Gross Profit | 526 526 |
35%
35%
|
|
EBITDA | -76 -76 |
38%
38%
|
EBIT (Operating Income) EBIT | -93 -93 |
33%
33%
|
Net Profit | -205 -205 |
50%
50%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
Head office | United States |
CEO | John Sheridan |
Employees | 2,650 |
Founded | 2006 |
Website | www.tandemdiabetes.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.